What ADHD medications are appropriate for a patient diagnosed with trichotillomania?

ADHD Medication Selection in Patients with Trichotillomania

In patients with trichotillomania and ADHD, non-stimulant medications—specifically atomoxetine, guanfacine, or clonidine—should be used as first-line treatment, as stimulants (methylphenidate and amphetamines) have been directly associated with inducing or worsening trichotillomania.

Critical Safety Concern: Stimulants and Trichotillomania

Multiple case reports document stimulant-induced trichotillomania that resolved upon discontinuation:

• Amphetamine/dextroamphetamine (Adderall) caused new-onset trichotillomania in a 12-year-old girl, which completely resolved after switching to guanfacine 1
• Methylphenidate and lisdexamfetamine both triggered trichotillomania in pediatric patients treated for ADHD 2
• Amphetamine abuse in adults has been linked to trichotillomania that resolved with stimulant cessation 3

This represents a direct contraindication to stimulant use in your patient, despite stimulants being the typical first-line ADHD treatment.

Recommended Medication Algorithm

First-Line Options (Non-Stimulants)

1. Atomoxetine (Preferred Initial Choice)

• Selective norepinephrine reuptake inhibitor with proven ADHD efficacy 4
• Effect size of 0.7 for ADHD symptoms (moderate, but acceptable) 4
• No association with trichotillomania induction or worsening 4
• Dosing: Start low, titrate over 6-12 weeks to therapeutic effect 4
• Monitor: Suicidality, pulse, clinical worsening 4
• Advantage: "Around-the-clock" symptom coverage without rebound effects 4

2. Extended-Release Guanfacine (Alternative First-Line)

• Alpha-2 adrenergic agonist, FDA-approved for ADHD 4
• Effect size of 0.7 for ADHD core symptoms 4
• Successfully used as replacement therapy when stimulants caused trichotillomania 1
• Particularly beneficial as first-line in comorbid tic disorders 4, 5
• Dosing: Titrate over 2-4 weeks; administer in evening due to sedation 4
• Monitor: Blood pressure, pulse, somnolence 4

3. Extended-Release Clonidine (Alternative First-Line)

• Alpha-2 adrenergic agonist with Level A evidence for ADHD with tics 5
• Similar efficacy profile to guanfacine 4
• Dosing: Twice daily may be required; transdermal patch available 4
• Monitor: Blood pressure, pulse, sedation 4
• Recommended as first-line when tic disorders coexist with ADHD 5

Treatment Sequencing

If first non-stimulant fails:

• Switch to alternative non-stimulant class (e.g., atomoxetine to guanfacine or vice versa) 4
• Ensure adequate trial: 6-12 weeks for atomoxetine, 2-4 weeks for alpha-2 agonists 4

Combination therapy:

• Non-stimulants can be combined with each other if monotherapy insufficient 4
• Avoid adding stimulants given the trichotillomania diagnosis

Age-Specific Considerations

Elementary school-aged children (6-11 years):

• FDA-approved medications include atomoxetine, extended-release guanfacine, and extended-release clonidine 4
• Behavioral therapy should be combined with medication 4

Adolescents (12-18 years):

• Same medication options with adolescent assent required 4
• Behavioral interventions may be less effective than in younger children 4

Critical Monitoring Parameters

For all non-stimulants:

• Height and weight at baseline and regularly 4
• Blood pressure and pulse (quarterly minimum) 4
• Trichotillomania symptoms (ensure no worsening) 1, 2

For atomoxetine specifically:

• Suicidality monitoring, especially in first weeks 4
• Clinical worsening or mood changes 4

For alpha-2 agonists:

• Sedation/somnolence (common, may improve with evening dosing) 4
• Hypotension and bradycardia 4
• Avoid abrupt discontinuation (rebound hypertension risk) 4

Common Pitfalls to Avoid

1. Do not use stimulants as first-line despite their superior efficacy in typical ADHD, given the documented association with trichotillomania 1, 2, 3

2. Do not expect immediate results with non-stimulants—allow 6-12 weeks for atomoxetine and 2-4 weeks for alpha-2 agonists before declaring treatment failure 4

3. Do not dismiss the smaller effect size of non-stimulants (0.7 vs 1.0 for stimulants)—they still provide clinically meaningful improvement and are safer in this population 4

4. Do not overlook behavioral interventions—parent training and behavioral classroom management should accompany medication in school-aged children 4

5. Do not ignore the trichotillomania itself—consider concurrent treatment with N-acetylcysteine (emerging evidence for trichotillomania) and cognitive-behavioral therapy 6, 7